A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

NCT00787202

Last updated date
Study Location
Pfizer Investigational Site
Antwerpen, , 2020, Belgium
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ulcerative Colitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must be at least 18 years of age at screening

- Males and female patients with clinical diagnosis of ulcerative colitis ≥3 months prior to entry into the study.

- Male and female patients with active currently moderate to severe ulcerative colitis defined by Mayo score of ≥6

- Patients with endoscopic sub-score of ≥2 on the Mayo score determined within 7 days of baseline.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Diagnosis of Crohn's disease or diagnosis of indeterminate colitis


- Treatment naive subjects who have not had previous exposure to treatment for
ulcerative colitis


- Patients that are currently receiving immunosuppressants, anti-TNFα therapy or
interferon

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Ulcerative ColitisTITRATE (inducTIon for acuTe ulceRATivE Colitis)
NCT03937609
  1. Amsterdam,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisTofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
NCT03772145
  1. Chapel Hill, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisA Fasting Mimicking Diet on Ulcerative Colitis Patients Undergoing Tofacitinib Induction
NCT04505410
  1. Miami, Florida
  2. Miami, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisTofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT04424303
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
Official Title  ICMJE A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study In Order To Investigate Safety And Efficacy Of CP- 690 550 In Subjects With Moderate To Severe Ulcerative Colitis.
Brief Summary The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Ulcerative Colitis
Intervention  ICMJE
  • Drug: CP- 690 550
    Administration via oral route twice daily for the duration of treatment
  • Other: placebo
    Administration via oral route twice daily for the duration of treatment
Study Arms  ICMJE
  • Experimental: 15 mg BID
    Intervention: Drug: CP- 690 550
  • Experimental: 10 mg BID
    Intervention: Drug: CP- 690 550
  • Experimental: 3 mg BID
    Intervention: Drug: CP- 690 550
  • Experimental: 0.5 mg BID
    Intervention: Drug: CP- 690 550
  • Placebo Comparator: Placebo
    Intervention: Other: placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 6, 2013)
195
Original Estimated Enrollment  ICMJE
 (submitted: November 6, 2008)
192
Actual Study Completion Date  ICMJE September 2010
Actual Primary Completion Date September 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must be at least 18 years of age at screening
  • Males and female patients with clinical diagnosis of ulcerative colitis ?3 months prior to entry into the study.
  • Male and female patients with active currently moderate to severe ulcerative colitis defined by Mayo score of ?6
  • Patients with endoscopic sub-score of ?2 on the Mayo score determined within 7 days of baseline.

Exclusion Criteria:

  • Diagnosis of Crohn's disease or diagnosis of indeterminate colitis
  • Treatment naive subjects who have not had previous exposure to treatment for ulcerative colitis
  • Patients that are currently receiving immunosuppressants, anti-TNF? therapy or interferon
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Brazil,   Chile,   Czech Republic,   Denmark,   France,   Hungary,   Israel,   Italy,   Mexico,   Netherlands,   Poland,   Slovakia,   South Africa,   Spain,   Sweden,   United Kingdom
Removed Location Countries Turkey
 
Administrative Information
NCT Number  ICMJE NCT00787202
Other Study ID Numbers  ICMJE A3921063
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP